Kiora Pharmaceuticals (KPRX) Q2 2025 earnings summary

Executive summary

• Focused on therapies for ophthalmic diseases, with KIO-301 and KIO-104 as lead candidates and both in Phase 2 trials (KLARITY and ABACUS-2) for retinal conditions.

• Entered a $16M global licensing deal for KIO-301 (excluding Asia) with TOI and a $1.25M upfront option agreement with Senju for Asian rights, with potential deal value up to $110M plus royalties.

• Extended KIO-104 market exclusivity to 2043 with new patent coverage.

• Sufficient cash and investments to fund operations into late 2027.

• Initiated Phase 2 clinical trials for KIO-301 and KIO-104 in 2025.

Financial highlights

• Six months ended June 30, 2025: total revenue $20,000, down from $16.02M year-over-year due to prior period's $16M TOI upfront payment.

• Net loss of $4.35M for the six months ended June 30, 2025, compared to net income of $11.23M in the prior year period.

• Ended Q2 2025 with $20.7M in cash, cash equivalents, and short-term investments.

• R&D expenses were $2.6M before $1.7M in reimbursable expenses; G&A expenses decreased to $1.4M from $1.5M year-over-year.

• Raised $13.8M in a private placement in February 2024.

Outlook and guidance

• Anticipates sufficient liquidity to fund planned operations into late 2027, beyond anticipated data readouts for both KLARITY and ABACUS-2 trials.

• Expects continued operating losses as clinical development progresses.

• Plans to seek additional financing through equity, debt, or partnerships as needed for future growth.

• Anticipates further extension of runway through achievement of partnership milestones.